Literature DB >> 11432807

Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.

B L Goodwin1, H Xi, R Tejiram, D D Eason, N Ghosh, K L Wright, U Nagarajan, J M Boss, G Blanck.   

Abstract

Melanoma cells commonly express MHC class II molecules constitutively. This is a rare, or possibly unique, phenotype for a nonprofessional antigen-presenting cell, where MHC class II expression ordinarily occurs only after IFN-gamma treatment. Despite the fact that constitutive expression of MHC class II on melanoma cells has been observed for decades and that the regulation of the MHC class II genes is well understood for many different cell types, there is no data regarding the basis for constitutive MHC class II expression in melanoma cells. Here we report that MHC class II expression in melanoma cells can be traced to constitutive expression of the class II transactivator protein (CIITA), which mediates both IFN-gamma-inducible and -constitutive MHC class II expression in all other cell types. In addition, we determined that constitutive CIITA expression is the result of the activation of both the B cell-specific CIITA promoter III and the IFN-gamma-inducible CIITA promoter IV, the latter of which previously has never been known to function as a constitutive promoter in any cell type. The recently described B cell-related ARE-1 activity is important for promoter III activation in the melanoma cells. Constitutive promoter IV activation involves the IFN regulatory factor element (IRF-E), which binds members of the IRF family of proteins, although the major, IFN-gamma inducible member of this family, IRF-1, is not constitutively expressed in these cells. In cells with constitutively active promoter IV, the promoter IV IRF-E is most likely activated by IRF-2. The relevance of these results to the pathway of melanoma development is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432807

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

2.  Definition, epidemiology and magnitude of alcoholic hepatitis.

Authors:  Sarpreet Basra; Bhupinderjit S Anand
Journal:  World J Hepatol       Date:  2011-05-27

Review 3.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

4.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

5.  Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.

Authors:  Jiri Kohoutek; Dalibor Blazek; B Matija Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

6.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

7.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

Review 8.  GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity.

Authors:  Karen Taraszka Hastings
Journal:  Front Immunol       Date:  2013-12-04       Impact factor: 7.561

9.  The human, F-actin-based cytoskeleton as a mutagen sensor.

Authors:  Nicolette M Clark; Carlos A Garcia Galindo; Vandan K Patel; Michele L Parry; Rebecca J Stoll; John M Yavorski; Elizabeth P Pinkason; Edna M Johnson; Chelsea M Walker; Joseph Johnson; Wade J Sexton; Domenico Coppola; George Blanck
Journal:  Cancer Cell Int       Date:  2017-12-12       Impact factor: 5.722

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.